Docoh
Loading...

51 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
) IND – Investigational New Drug MTD – Maximum Tolerated Dose SPA – FDA Special Protocol Assessment Our Annual Report on Form 10-K for the year ended
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
such returns would not result in a Material Adverse Change, and has paid all taxes due pursuant to such returns or pursuant to any assessment received
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
to have an end of Phase 2 meeting with the FDA to agree on the design of the Phase 3 study, to define a Special Protocol Assessment for the Phase 3 study
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
meeting with the FDA to agree on the design of the Phase 3 study, to define a Special Protocol Assessment for the Phase 3 study and to agree
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
a Special Protocol Assessment for the Phase 3 study and to agree on the next steps to obtain approval. PCS12852 On August 19, 2020, we in-licensed PCS12852 … medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods
8-K
EX-10.2
ux97jxxp
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
bn7fm3d
12 Nov 20
Quarterly report
4:01pm
424B4
vgd4b0ig0j2xp
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
y7lbjdxb0pimzjhwqoe
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
zbf307zbvaxi1y
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
qk3a3bdx n89b2q
16 Sep 20
IPO registration (amended)
8:00pm
10-Q
n0p6508 xrswu43w3if
5 Aug 20
Quarterly report
3:32pm
S-1/A
30hywrb9whtrq z15r
17 Jul 20
IPO registration (amended)
5:25pm
10-Q
1bu1kzdt
15 May 20
Quarterly report
1:23pm
8-K
EX-99.1
8zoy7
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
10-K
0i131d27hgm5
5 Mar 20
Annual report
7:00pm
S-1
rbmfec n6nzd
13 Dec 19
IPO registration
5:32pm
10-K/A
t5m m5g35mmpz
5 Apr 19
Annual report (amended)
9:40pm
10-K
sxwgieoxowgiqok
28 Mar 19
Annual report
5:25pm
424B3
qj9ed0lz d7rie
9 Nov 18
Prospectus supplement
5:04pm